[go: up one dir, main page]

HK1130069A1 - 肿瘤抑制基因wt1的产物作为肿瘤抗原 - Google Patents

肿瘤抑制基因wt1的产物作为肿瘤抗原 Download PDF

Info

Publication number
HK1130069A1
HK1130069A1 HK09109542.5A HK09109542A HK1130069A1 HK 1130069 A1 HK1130069 A1 HK 1130069A1 HK 09109542 A HK09109542 A HK 09109542A HK 1130069 A1 HK1130069 A1 HK 1130069A1
Authority
HK
Hong Kong
Prior art keywords
cells
cancer
peptide
tumor
amino acid
Prior art date
Application number
HK09109542.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1130069B (zh
Inventor
Sugiyama Haruo
Oka Yoshihiro
Original Assignee
International Institute Of Cancer Immunology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1130069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by International Institute Of Cancer Immunology, Inc. filed Critical International Institute Of Cancer Immunology, Inc.
Publication of HK1130069A1 publication Critical patent/HK1130069A1/zh
Publication of HK1130069B publication Critical patent/HK1130069B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09109542.5A 1998-07-31 2009-10-15 肿瘤抑制基因wt1的产物作为肿瘤抗原 HK1130069B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
JP21809398 1998-07-31

Publications (2)

Publication Number Publication Date
HK1130069A1 true HK1130069A1 (zh) 2009-12-18
HK1130069B HK1130069B (zh) 2015-07-31

Family

ID=

Also Published As

Publication number Publication date
EP2048160B1 (en) 2015-01-07
US20090281043A1 (en) 2009-11-12
EP2048160A1 (en) 2009-04-15
JP4422903B2 (ja) 2010-03-03
EP2280031B1 (en) 2015-04-15
US7807792B2 (en) 2010-10-05
CN1762490A (zh) 2006-04-26
WO2000006602A1 (fr) 2000-02-10
US20060093615A1 (en) 2006-05-04
CA2337743C (en) 2015-07-07
CN102198266A (zh) 2011-09-28
HK1153761A1 (zh) 2012-04-05
EP1103564A4 (en) 2005-02-02
CN1178956C (zh) 2004-12-08
ATE420112T1 (de) 2009-01-15
EP1103564B1 (en) 2009-01-07
HK1036073A1 (zh) 2001-12-21
BRPI9912663B8 (pt) 2021-07-06
CN100560130C (zh) 2009-11-18
US7517950B2 (en) 2009-04-14
US7390871B2 (en) 2008-06-24
EP1103564A1 (en) 2001-05-30
JP5230579B2 (ja) 2013-07-10
US7608685B1 (en) 2009-10-27
CA2337743A1 (en) 2000-02-10
CN1314916A (zh) 2001-09-26
HK1038929B (zh) 2005-05-06
US20160243209A1 (en) 2016-08-25
BRPI9912663B1 (pt) 2011-05-31
US9403886B2 (en) 2016-08-02
KR20010072112A (ko) 2001-07-31
JP2010059172A (ja) 2010-03-18
ES2318898T3 (es) 2009-05-01
PT1103564E (pt) 2009-03-13
CN1560078A (zh) 2005-01-05
DE69940264D1 (de) 2009-02-26
KR100767554B1 (ko) 2007-10-17
BRPI9912663A (pt) 2001-05-02
US20050266014A1 (en) 2005-12-01
US7030212B1 (en) 2006-04-18
AU4932199A (en) 2000-02-21
US20090143291A1 (en) 2009-06-04
EP2280031A1 (en) 2011-02-02
HK1038929A1 (zh) 2002-04-04
CN1560078B (zh) 2011-06-22
DK1103564T3 (da) 2009-05-11

Similar Documents

Publication Publication Date Title
EP2048160B1 (en) Tumor antigen based on products of the tumor suppressor gene WT1
CA2440303C (en) Wt1 modified peptide
US6759046B1 (en) Peptides
JPWO2000006602A1 (ja) 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
CA2451846A1 (en) Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
US6555652B1 (en) Tumor antigen peptide derivatives
JP4436977B2 (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
HK1130069B (zh) 肿瘤抑制基因wt1的产物作为肿瘤抗原
HK1153761B (zh) 以肿瘤抑制基因wt1的产物作为肿瘤抗原
HK1036073B (zh) 利用肿瘤抑制性基因wt1产物产生的癌抗原
US6514493B1 (en) cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine
EP1562622A2 (en) Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190729